#ESMO26 1003O: Ph1 study of IM96, a #GCC-targeted #CART therapy, in heavily pre-treated #CRC (4L+). ORR 42%, with G3 CRS in 10%. Promising efficacy in a setting with few options…

TapiaJC1· @TapiaJC1 · X·2026-10-19 08:01· 5 天前评分60

正文 · 原文

#ESMO26 1003O: Ph1 study of IM96, a #GCC-targeted #CART therapy, in heavily pre-treated #CRC (4L+). ORR 42%, with G3 CRS in 10%. Promising efficacy in a setting with few options. #ColonCancer @myESMO @OncoAlert

热度 0 · 0 赞 · 0 回复 · 0 转发

来源：TapiaJC1 · x.com